Overcoming Etoricoxib Tableting Challenges With FujiCalin®

See the latest edition of the Fuji Chemical Technical Newsletter:

Why Etoricoxib is Difficult to Formulate?

Etoricoxib, a selective COX-2 inhibitor marketed under brands such as Arcoxia, is especially challenging to formulate. The needle-like morphology of its API crystals results in significant sticking during tablet compression and complicates manufacturing reproducibility. Additionally, Etoricoxib’s dissolution performance is optimal in a neutral to mildly basic pH range (7-8.5), necessitating specialized excipients for stable, efficient oral absorption.

Overcoming Etoricoxib Formulation Challenges with Fujicalin®

Traditional tableting excipients often fail to “cushion” needle-shaped API crystals during compaction, leading to sticking and wear on machinery, negatively affecting yield and batch quality.

Fujicalin®, a patented, proprietary, spray dried, spherically granulated Dibasic Calcium Phosphate Anhydrous (DCPA), mitigates this issue through its unique particle morphology and high porosity. Its smooth, spherical granules are less abrasive and effectively prevent physical damage to both active crystals and compression tooling, leading to trouble-free and consistent operations.

Roller Compaction and Tablet Uniformity

Fujicalin® excels under the repeated pressure cycles encountered during roller compaction – a key process for high-volume tablet production. Unlike conventional DCPA excipients, Fujicalin® retains high tablet porosity and hardness even at low compression forces. This directly translates to better tablet integrity, content uniformity, and reduced friability.

pH Modulation and Dissolution Enhancement

Etoricoxib’s dissolution is reliant on a near-neutral to mildly basic environment. Additionally, Etoricoxib’s dissolution performance is optimal in a neutral to mildly basic pH range (7-8.5), necessitating specialized excipients for stable, efficient oral absorption.

Fujicalin® offers an inherent nearneutral pH in aqueous suspension, which stabilizes API dissolution kinetics and promotes optimal bioavailability. Its high specific surface area amplifies drug dissolution, physical stability, and absorption which are key concerns when dealing with poorly soluble drugs like Etoricoxib.

CASE STUDY:
Formulation of Etoicoxib Tablets Using FujiCalin®

A proposed approach for Etoricoxib tablet development incorporates Fujicalin® at concentrations of 30-70%. Key functional benefits include:

Formulators can achieve improved batch consistency, reduced machine downtime, and an ability to accommodate advanced tablet designs (liquisolid, SEDDS, probiotic) when using Fujicalin®.

Conclusion

The integration of Fujicalin® into Etoricoxib tablet formulations represents a significant advancement in overcoming active ingredient morphology and dissolution rate limitations. By combining unique surface and porosity characteristics, a stable pH profile, and robust compression abilities, Fujicalin® enables manufacturers to produce high-quality Etoricoxib tablets with consistent performance and regulatory compliance.

Its versatility in direct compression, roller compaction, liquid handling, and content uniformity makes it an indispensable tool in pharmaceutical innovation for poorly watersoluble drugs and challenging APIs.

Continue reading and see the full Pharmaceutical Technical Newsletter on Overcoming Etoricoxib Tableting Challenges here:

(click the picture to download the technical newsletter)

MORE ON FUJI CHEMICAl

Source: Fuji Chemical Industries technical newsletter Overcoming Etoricoxib Tableting Challenges

Read also the other Technical Newsletter of Fuji Chemical Industries here:

• Issue 01 2025 – Fujicalin®: Revolutionizing Axitinib Delivery with Liquisolid Technology
• Special Issue – Fujicalin®: Your Partner in Mitigating Nitrosamine Impurities in Drug Products
• Special Issue – pH Independent Bi-layer Self-microemulsifying Tablets (SMETs) of Candesartan Cilexetil with Fujicalin® and Neusilin®
• Special Issue – Mitigating Nitrosamine Risks in Drug Products
• Newsletter: F-MELT® Type C: Pioneering Patient – Friendly Fast – Dissolving Tablets

Do you need more information or a sample of Fuji Chemical Industries excipients?